


AD-A168 094 ANTIMALARIAL CYCLIC PEROXIDE LACTONES(U) NORTH CAROLINA 1/1
UNIV AT CHAPEL HILL K LEE 15 MAY 85 DAND17-83-C-3898

UNCLASSIFIED

F/G 6/15

NL





MICROCOPY RESOLUTION TEST CHART

AD-A168 094

AD

①

"ANTIMALARIAL CYCLIC PEROXIDE LACTONES"

ANNUAL REPORT

KUO-HSIUNG LEE

May 15, 1985

DTIC
ELECTE
MAY 30 1986
S B D

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-83-C-3098

University of North Carolina
Chapel Hill, North Carolina 27514

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution unlimited

The findings in this report are not to be construed as
an official Department of the Army position unless so
designated by other authorized documents.

DTIC FILE COPY


36 5 25

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Antimalarial Cyclic Peroxide Lactones		5. TYPE OF REPORT & PERIOD COVERED Annual Report 2/14/84-9/14/84
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Dr. Kuo-Hsiung Lee		8. CONTRACT OR GRANT NUMBER(s) DAMD 17-83-C-3098
9. PERFORMING ORGANIZATION NAME AND ADDRESS School of Pharmacy University of North Carolina Chapel Hill, North Carolina 27514		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
11. CONTROLLING OFFICE NAME AND ADDRESS U. S. Army Medical Research and Development Command, Fort Detrick, Frederick, Maryland 21701		12. REPORT DATE 5/15/85
		13. NUMBER OF PAGES eight
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report) Unclassified
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Approved for public release; distribution unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Antimalarial agents; 15-methylcarbamoyl bruceolide; 15-phenylalaninyl bruceolide		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) 15-Methylcarbamoyl bruceolide and 15-phenylalaninyl bruceolide were synthesized from brusatol, obtained by acid hydrolysis of bruceoside-A, by an initial protection of the 3-hydroxyl group as a dimethyl-t-butylsilyl ether followed by base hydrolysis of the C-15 ester side chain, reacylation with methyl isocyanate and N-t-butoxycarbonyl L-phenylalanine anhydride, respectively, and deblocking of the silyl moiety with 80% acetic acid and tetrabutylammonium fluoride, respectively.		

Lee, K. H.
DAMD 17-83-C-3098

ANNUAL REPORT

- (1) List of structures of all target compounds that have been submitted to the Walter Reed Army Institute of Research for screening between February 14, 1984 - September 14, 1984.



1. R = NHCH₃ (430 mg) (15-methylcarbamoyl bruceolide)
BK84184
2. R = $\begin{array}{c} \text{CH}-\text{CH}_2-\text{C}_6\text{H}_5 \\ | \\ \text{NH}_2 \end{array}$ (500 mg) (15-phenylalaninyl bruceolide)

Accession For	
NTIS	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

3

(2) Synthetic procedures for each target compound listed above

The synthesis of 15-methylcarbamoyl bruceolide (XII) and 15-phenylalaninyl bruceolide (XVI) was based upon the discussion and recommendation in a telephone conversation with Dr. H. A. Musallam, Department of Medicinal Chemistry, Division of Experimental Therapeutics, Walter Reed Army Institute of Research on March 1, 1984.

1. 15-Methylcarbamoyl bruceolide (XII) (Scheme-1):

- a. The synthesis of XII employed a procedure using brusatol as a starting material. Compound IX, prepared from brusatol was described on page 5 of my "annual Report" which was submitted previously on February 13, 1984.
- b. Synthesis of Compound XI: To a solution of IX (530 mg) in absolute benzene (50 mL) was added MeNCO (82 mg). The mixture, after stirred at room temp. for 30 hrs., was washed with saturated NaCl solution, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield a residue. Recrystallization of this residue from ether-petroleum ether afforded XI (480 mg, 82% yield) as white prisms: mp 145-157°; IR ($CHCl_3$) 3450, 3550 (OH and NH), and 1730 ($C=O$) cm^{-1} ; NMR (250 MHz, $CDCl_3$) δ 5.95 (1H, d, $J = 15$ Hz, H-15), 5.40 (1H, br. s, NH), 4.83 (1H, br. s, H-7), 4.71, 3.75 (2H, d each, $J = 7.5$ Hz, H-17), 4.24 (2H, br. s, H-11 and H-12), 3.79 (3H, s, $COOCH_3$), 2.80 (3H, d, $J = 5.6$ Hz, N- CH_3), 1.86 (3H, s, CH_3 -4), 1.39 (3H, s, CH_3 -10), 0.96 (9H, s, Si-t-butyl group), 0.16, 0.15 (6H, s each, $SiMe_2$) and 2.97 (1H, d, $J = 15.0$ Hz, H-14).
Anal. Calcd for $C_{29}H_{43}O_{11}$ N Si: m/z 609.2596. Found: m/z 609 (M^+); for $C_{25}H_{34}O_{11}$ N Si ($M^+ - C_4H_9$): m/z 552.1898. Found: m/z 552.1898.
- c. Synthesis of 15-Methylcarbamoyl Bruceolide (XII): A solution of XI (222 mg, 0.36 mmol) in 80% acetic acid (2 mL) was heated at 80°C for 1.5 hr with stirring. After the acetic acid was evaporated in vacuo, the residue was added with water (10 mL). The water-insoluble substances were filtered. The filtrate was evaporated under reduced pressure to give an oil (150 mg) which showed two spots on TLC (silica gel - EtOAc). Separation and isolation of Compound XII (80 mg) was achieved by PTLC (silica gel - EtOAc). Compound XII (50% yield) was recrystallized from acetone-ether: mp 204-206°; IR (IBr) 3600-3200 (br., OH, NH), 1730 (ester and lactone CO), 1640 ($OCONHMe$), and 1660 (α, β -unsat. CO) cm^{-1} ; NMR (250 MHz, $DMSO-d_6$ -TMS) δ 7.77 (1H, br. s, NH), 5.44 (1H, br. s, H-15), 4.92 (1H, br. s, H-7), 4.42, 3.69 (2H, d each, $J = 7.5$ Hz, H-17), 4.06 (1H, s, H-12), 4.02 (1H, d, $J = 7.5$ Hz, H-11), 3.69 (3H, s, $COOCH_3$), 2.86 (3H, s, N- CH_3), 2.76 (1H, d, $J = 15.0$ Hz, 14-H), 2.76 (2H, q, $J = 5.0$ Hz, H-1), 2.11 (1H, dd, $J = 15.0$ Hz and 2.0 Hz, H-5), 1.81 (2H, dt, $J = 15.0$ Hz and 2.0 Hz, H-6), 1.69 (3H, s, CH_3 -4) and 1.17 (3H, s, CH_3 -10).
Anal. Calcd for $C_{23}H_{29}O_{11}$ N: m/z 495.1739. Found: m/z 495.1722.

- d. Considerable efforts were made to remove the dimethyl-t-butylsilyl protecting group from IX in order to make XII. When XI was treated with tetrabutylammonium fluoride in THF at room temperature, Compound XIII instead of Compound XII was obtained in ca. 80% yield.

2. 15-Phenylalaninyl bruceolide (XVI) (Scheme-1):

- a. Synthesis of Compound XIV - To a stirred solution of IX (600 mg) in anhydrous benzene (30 mL) was added freshly distilled anhydrous pyridine (2 mL) and N-tert butoxycarbonyl-L-phenylalanine anhydride¹ (700 mg). After 20 hr, the mixture was washed with water, diluted HCl, water, NaHCO₃, saturated NaCl and water. The benzene layer was dried over anhydrous MgSO₄ and evaporated *in vacuo* to yield a residue (800 mg). Recrystallization of this residue from ether afforded XIV as colorless needles (630 mg, 72% yield): mp 233-235°; IR (KBr) 3600-3400 (OH and NH), 1740 (lactone CO), 1725 (ester CO), 1670 (NHCO), 1640 (C=C-CO) and 1610 (C=C-CO) cm⁻¹; NMR (250 MHz, CDCl₃) δ 0.15, 0.16 (3H each, s) (SiMe₂), 0.93 (9H, s, SiMe₃), 1.35 (9H, s, O-CMe₃), 1.38 (3H, s, Me-10), 1.83 (3H, s, Me-4), 2.02 (H-9), 2.34 (2H, m, H-6 and H-1), 2.92 (2H, m, H-6 and H-1), 3.19 (1H, d, J = 7.50 Hz, H-14), 3.79 (3H, s, COOMe), 4.24 (2H, brm, H-11 and H-12), 3.75, 4.69 (2H, d each, J = 7.50 Hz, H-17), 4.78 (1H, s-like, H-7), 6.30 (1H, d, H-15) and 7.27 (5H, aromatic protons).
Anal. Calcd for C₄₁H₅₇O₁₃N Si: m/z 799.3583. Found: m/z 742 [M⁺-57 (t-BOC group)] and m/z 784 [M⁺-15 (Me group)].
- b. Synthesis of XV - To a stirred solution of XIV (1.23 g, 1.53 mmol) in THF (8 mL) was added Bu₄N⁺ F⁻ (4 mL, 4 mmol) at 0°. After 10 min., the reaction mixture was poured into iced water (20 mL) and extracted with chloroform. The chloroform extract was washed with water, 3% aqueous Na₂CO₃ and water, dried over anhydrous MgSO₄, and evaporated under reduced pressure to give a residue. Recrystallization from EtOAc-ether yielded XV as colorless prisms (990 mg, 94% yield): mp 213-215°; TLC [silica gel, EtOAc-CHCl₃ (1:1), R_f = 0.3]; IR (KBr) 3550-3300 (OH and NH), 1740 and 1720 (lactone and ester CO), 1640 (NHCO) and 1610 (α,β -unsat. CO) cm⁻¹; NMR (250 MHz, CDCl₃) δ 1.35 (9H, s, CMe₃), 1.39 (3H, s, Me-10), 1.84 (3H, d, J = 1.0 Hz, Me-4), 3.20 (2H, d-like, J = 13.0 Hz, CH₂Ph), 3.81 (3H, s, COOMe), 4.26 (2H, m, H-11 and H-12), 4.53 (1H, m, CH-CH₂Ph), 3.75, 4.70 (1H each, d, J = 7.5 Hz, H-17), 4.77 (1H, s-like, H-7), 5.00 (1H, d, J = 11.0 Hz, NHCO), 6.32 (1H, d, J = 13.0 Hz, H-15) and 7.27 (5H, m, aromatic protons).
Anal. Calcd for C₃₅H₄₃O₁₃N: m/z 685.2747. Found (FAB): m/z 686 (M⁺ + H) and m/z 586 [M⁺-99 (t-BOC)].
- c. Synthesis of XVI - A solution of XV (830 mg) in anhydrous EtOAc (20 mL) was cooled to 0°, and anhydrous HCl gas was introduced

into this solution for about 40 min. The reaction mixture was allowed to stand at 0° for 30 min in the nitrogen atmosphere. The resulting crystals were filtered, washed with cold EtOAc and dried to furnish XVI (700 mg, 93% yield) as colorless needles: mp 225-227°; TLC (silica gel, EtOAc, Rf = 0.40); IR (KBr) 3500-3200 (OH and NH₂), 1760 (lactone CO) and 1740 (ester CO) cm⁻¹; NMR (250 MHz, CD₃OD) 1.38 (3H, s, Me-10), 1.84 (3H, s, Me-4), 1.90 (1H, d, J = 5.1 Hz, H-9), 3.00 (1H, H-5), 2.55, 2.86 (1H each, d, J = 15.0 Hz, H-1), 3.44 (1H, d, J = 15.0 Hz, H-14), 3.69 (3H, s, COOMe), 3.06, 3.34 (1H each, q, J = 15.0, 4.0 and 15.0, 7.0 Hz, H-23), 4.38 (1H, q, J = 4.0 and 7.0 Hz, H-22), 4.18 (1H, d, J = 5.6 Hz, H-11), 4.32 (1H, s-like, H-12), 3.72, 4.70 (1H each, d, J = 7.0 Hz, H-17), 4.92 (1H, m, H-7), 6.37 (1H, d, J = 15.0 Hz, H-15) and 7.35 (5H, m, aromatic protons).

Anal. Calcd for C₃₀H₃₅O₁₁N·HCl· $\frac{5}{3}$ H₂O: C 55.25%, H 6.08% and N 2.14%. Found: C 55.09%, H 6.30% and N 2.51%.

Also Anal. Calcd for C₃₀H₃₅O₁₁N (FAB): m/z 585 (M⁺). Found: m/z 586 (M⁺ + H).

(3) Literature references -

1. D. H. Rammner and H. G. Khorana, J. Am. Chem. Soc., **85**, 1997 (1963).

(4) Biological test data -

These are not available as testing on compounds listed above in (1) is in progress by Walter Reed Army Institute of Research.

(5) Publication and patents -

1. These will be considered upon the completion of biological testing.
2. "Antimalarial Agents. 1. α -Santonin-Derived Cyclic Peroxide as Potential Antimalarial Agent" by S. Tani, N. Fukamiya, H. Kiyokawa, H. A. Musallam, R. O. Pick and K. H. Lee, J. Med. Chem., in press. This publication is based upon data presented in my Annual Report submitted February 13, 1984, p. 4.


(6) List of personnel receiving contract support -

1. Dr. Shohei Tani (2/14/84-9/14/84), Associate Professor of Pharmaceutical Chemistry, on leave from Kobe Gakuin University (Ph.D. from Kyoto University) worked continuously very hard on this project.

Lee, K. H.
DAMD 17-83-C-3098

2. Dr. Hiroshi Irie, Professor of Pharmaceutical Chemistry at Nagasaki University participated in the discussion and the work of the synthetic analogs related to artemisinin beginning July 1, 1984 through August 31, 1984. Dr. Irie is a distinguished synthetic organic chemist with more than 80 publications in the synthesis of natural products.

Scheme 1



END
DITIC

7-86